(EVK) Evonik Industries - Ratings and Ratios
Specialty Additives, Nutrition Care, Smart Materials, Technology Infrastructure
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 6.14% |
| Yield on Cost 5y | 5.65% |
| Yield CAGR 5y | 0.43% |
| Payout Consistency | 96.5% |
| Payout Ratio | - |
| Risk via 5d forecast | |
|---|---|
| Volatility | 22.9% |
| Value at Risk 5%th | 36.8% |
| Relative Tail Risk | -2.36% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.03 |
| Alpha | -30.77 |
| CAGR/Max DD | -0.21 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.421 |
| Beta | 0.223 |
| Beta Downside | 0.403 |
| Drawdowns 3y | |
|---|---|
| Max DD | 39.76% |
| Mean DD | 12.43% |
| Median DD | 10.54% |
Description: EVK Evonik Industries January 07, 2026
Evonik Industries AG (XETRA:EVK) is a global specialty chemicals producer headquartered in Essen, Germany, operating across four business segments: Specialty Additives, Nutrition & Care, Smart Materials, and Technology & Infrastructure. The company supplies a wide range of high-performance chemicals-from polyurethane foam additives and curing agents for coatings to amino acids for animal nutrition and biocompatible materials for medical devices-serving markets in Asia-Pacific, Europe, the Middle East, Africa, the Americas, and beyond.
Key recent metrics: FY 2023 revenue reached €15.2 billion, with an adjusted EBITDA margin of roughly 14%, reflecting strong pricing power in the Specialty Additives and Smart Materials divisions. Growth is being driven by secular trends such as the automotive sector’s shift toward lightweight, fuel-efficient vehicles (boosting demand for polyamide 12 and specialty polymers) and the broader industrial push for decarbonisation, which fuels sales of high-efficiency additives and digital process-optimization services. The Nutrition & Care segment benefits from rising global protein demand, supporting higher volumes of methionine and lysine for animal feed.
For a deeper quantitative assessment, consider reviewing ValueRay’s detailed EVK valuation model.
Piotroski VR‑10 (Strict, 0-10) 4.0
| Net Income: 95.0m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.02 > 0.02 and ΔFCF/TA -3.69 > 1.0 |
| NWC/Revenue: 13.02% < 20% (prev 10.46%; Δ 2.56% < -1%) |
| CFO/TA 0.07 > 3% & CFO 1.22b > Net Income 95.0m |
| Net Debt (4.04b) to EBITDA (1.78b): 2.27 < 3 |
| Current Ratio: 1.54 > 1.5 & < 3 |
| Outstanding Shares: last quarter (466.0m) vs 12m ago 0.30% < -2% |
| Gross Margin: 22.56% > 18% (prev 0.25%; Δ 2231 % > 0.5%) |
| Asset Turnover: 74.87% > 50% (prev 77.51%; Δ -2.64% > 0%) |
| Interest Coverage Ratio: 2.21 > 6 (EBITDA TTM 1.78b / Interest Expense TTM 217.0m) |
Altman Z'' 2.87
| A: 0.10 (Total Current Assets 5.30b - Total Current Liabilities 3.45b) / Total Assets 18.55b |
| B: 0.40 (Retained Earnings 7.41b / Total Assets 18.55b) |
| C: 0.03 (EBIT TTM 480.0m / Avg Total Assets 19.05b) |
| D: 0.71 (Book Value of Equity 7.18b / Total Liabilities 10.13b) |
| Altman-Z'' Score: 2.87 = A |
Beneish M -3.04
| DSRI: 0.97 (Receivables 1.67b/1.83b, Revenue 14.27b/15.16b) |
| GMI: 1.12 (GM 22.56% / 25.25%) |
| AQI: 1.01 (AQ_t 0.35 / AQ_t-1 0.34) |
| SGI: 0.94 (Revenue 14.27b / 15.16b) |
| TATA: -0.06 (NI 95.0m - CFO 1.22b) / TA 18.55b) |
| Beneish M-Score: -3.04 (Cap -4..+1) = AA |
ValueRay F-Score (Strict, 0-100) 45.59
| 1. Piotroski: 4.0pt |
| 2. FCF Yield: 4.01% |
| 3. FCF Margin: 2.87% |
| 4. Debt/Equity: 0.54 |
| 5. Debt/Ebitda: 2.27 |
| 6. ROIC - WACC: -1.50% |
| 7. RoE: 1.08% |
| 8. Revenue Trend: -82.32% |
| 9. EPS Trend: data missing |
What is the price of EVK shares?
Over the past week, the price has changed by +2.54%, over one month by -2.41%, over three months by -12.86% and over the past year by -23.88%.
Is EVK a buy, sell or hold?
What are the forecasts/targets for the EVK price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 14.6 | 12.8% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 13.1 | 1.2% |
EVK Fundamental Data Overview January 27, 2026
P/E Trailing = 63.0
P/E Forward = 19.9203
P/S = 0.4322
P/B = 0.7384
P/EG = 5.0637
Revenue TTM = 14.27b EUR
EBIT TTM = 480.0m EUR
EBITDA TTM = 1.78b EUR
Long Term Debt = 3.66b EUR (from longTermDebt, last quarter)
Short Term Debt = 830.0m EUR (from shortTermDebt, last quarter)
Debt = 4.49b EUR (from shortLongTermDebtTotal, last quarter)
Net Debt = 4.04b EUR (from netDebt column, last quarter)
Enterprise Value = 10.20b EUR (6.17b + Debt 4.49b - CCE 454.0m)
Interest Coverage Ratio = 2.21 (Ebit TTM 480.0m / Interest Expense TTM 217.0m)
EV/FCF = 24.95x (Enterprise Value 10.20b / FCF TTM 409.0m)
FCF Yield = 4.01% (FCF TTM 409.0m / Enterprise Value 10.20b)
FCF Margin = 2.87% (FCF TTM 409.0m / Revenue TTM 14.27b)
Net Margin = 0.67% (Net Income TTM 95.0m / Revenue TTM 14.27b)
Gross Margin = 22.56% ((Revenue TTM 14.27b - Cost of Revenue TTM 11.05b) / Revenue TTM)
Gross Margin QoQ = 18.17% (prev 26.61%)
Tobins Q-Ratio = 0.55 (Enterprise Value 10.20b / Total Assets 18.55b)
Interest Expense / Debt = 1.25% (Interest Expense 56.0m / Debt 4.49b)
Taxrate = 44.70% (194.0m / 434.0m)
NOPAT = 265.4m (EBIT 480.0m * (1 - 44.70%))
Current Ratio = 1.54 (Total Current Assets 5.30b / Total Current Liabilities 3.45b)
Debt / Equity = 0.54 (Debt 4.49b / totalStockholderEquity, last quarter 8.35b)
Debt / EBITDA = 2.27 (Net Debt 4.04b / EBITDA 1.78b)
Debt / FCF = 9.88 (Net Debt 4.04b / FCF TTM 409.0m)
Total Stockholder Equity = 8.76b (last 4 quarters mean from totalStockholderEquity)
RoA = 0.50% (Net Income 95.0m / Total Assets 18.55b)
RoE = 1.08% (Net Income TTM 95.0m / Total Stockholder Equity 8.76b)
RoCE = 3.86% (EBIT 480.0m / Capital Employed (Equity 8.76b + L.T.Debt 3.66b))
RoIC = 2.69% (NOPAT 265.4m / Invested Capital 9.85b)
WACC = 4.19% (E(6.17b)/V(10.66b) * Re(6.74%) + D(4.49b)/V(10.66b) * Rd(1.25%) * (1-Tc(0.45)))
Discount Rate = 6.74% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Fair Price DCF = unknown (Cash Flow 409.0m)
Revenue Correlation: -82.32 | Revenue CAGR: -4.88% | SUE: N/A | # QB: 0